Identify the cream behind the web address
The official prescription Clear page calls the product a dark-spot lightener and corrector cream. Its address contains the word “serum,” which is a useful example of why a URL alone cannot establish dosage form. The visible product description, ingredient declaration and eventual dispensing label matter more than an address inherited from a website.
Obagi states that a prescription is required and directs readers to a healthcare provider or physician finder. The page does not provide a current purchase price or verify that a particular practice has stock. It also does not show that every person with discoloration is an appropriate candidate. A product locator is a route to an inquiry, not an assessment of the mark on someone’s face.
What the published ingredient list establishes
The current page identifies hydroquinone USP 4%, equivalent to 40 milligrams per gram. It also publishes inactive ingredients, including sodium metabisulfite, lactic acid and ascorbic acid. That is more informative than a headline mentioning hydroquinone alone. It still does not tell us how an individual will tolerate the preparation or establish concentrations for the inactive ingredients.
For someone with a previous reaction, the full list has practical value. Bring the particular product and reaction history to the pharmacist instead of asking whether every 4% cream is interchangeable. Our sulfite-label guide explains why sodium metabisulfite deserves a specific discussion. Its presence is not proof that everyone with sensitive skin or asthma will react, and its absence from another advertisement would not establish that the other product is sulfite-free.
The older label is useful, with a visible boundary
The DailyMed manufacturer record contains labeling revised March 2018 for Clear, Blender and Sunfader. It describes Clear as a 4% hydroquinone cream in a 57-gram bottle. That historical packaging detail does not verify the package a clinician would dispense today. The record covers several products, so a Sunfader sunscreen ingredient cannot be assigned to Clear.
The current Clear page and that older Clear label do not display identical inactive-ingredient lists. For example, the current page includes phenyl trimethicone and PPG-2 myristyl ether propionate, which are absent from the older Clear list. We cannot determine from those records alone whether a reformulation, a website error or another documentation issue explains the difference. Ask for the actual current label; silently combining the lists would create a product description neither source supplies.
Prescription status does not settle FDA approval
DailyMed explicitly states that this labeling has not been approved by FDA and that the drug has not been found by FDA to be safe and effective. That statement must remain visible beside the recognizable brand name. A prescription requirement, a listing in DailyMed and an NDC are separate facts from an approved drug application. Our approval-claims report explains the distinction.
FDA’s hydroquinone guidance identifies a specific approved combination product, Tri-Luma; that does not extend approval to every hydroquinone cream. Nor does this review conclude that every unapproved branded cream is a compounded preparation. The classification and evidence for the actual product need their own record. The practical question is which medicine is proposed, what its regulatory status is and how the clinician weighs its use against alternatives.
Clear Fx prices belong to Clear Fx
The Nu-Derm collection page includes nonprescription bestseller cards with prices. Its $125 Clear Fx card is not a verified price for prescription Clear. A search result or cropped screenshot can conceal that change in product identity. We leave the current prescription price unverified rather than importing a nearby number into this review.
Our separate Obagi Clear Fx review concerns the hydroquinone-free product. If a seller uses a shortened “Clear” name, request the complete name, ingredient declaration, quantity and all-in charge. Also ask whether consultation and later assessment are separate costs. Those details allow a real comparison with the provider shortlist without inventing a common monthly price for products sold on different terms.
Safety information belongs with the offer
Obagi’s current page warns about ingredient sensitivity, eye and mucosal contact, and sulfite reactions. It also identifies uncertainty in pregnancy and breastfeeding. An older pregnancy letter category on the page is not a personalized safety clearance. Our pregnancy and breastfeeding report separates those questions so a reader does not treat missing evidence as reassurance or choose a lower concentration as a workaround.
Hydroquinone can also cause unwanted darkening and skin reactions, as FDA’s safety information explains. A clinician should identify the condition and establish a review plan. A new, changing or symptomatic spot should not simply be relabeled a cosmetic pigment issue because a familiar cream is available. Sunscreen does not make every lesion suitable for depigmenting treatment.
What a useful Obagi inquiry looks like
Ask the practice to name the proposed product precisely and provide its current ingredient list. Request the quantity, total payable, dispensing source, follow-up arrangements and instructions for reporting a reaction. If the supplied label differs from the website, ask which record governs the dispensed preparation. A clear answer is more useful than assuming an older image accurately describes a current bottle.
We did not identify a direct trial in these sources comparing today’s exact Clear formulation with CoreAge’s advertised combination. Familiarity, percentage and commercial placement therefore cannot produce a clinical winner. The CoreAge Rx review has its own formulation and pricing limitations. Read both as preparation for a clinical discussion, with exact product identity and unresolved questions preserved.